Table 55. Patient characteristics–haloperidol versus ziprasidone

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Vieta et al. 2005**32 | ***Study design:*** RCT***Registration #:*** NR***Study population:*** Bipolar***DSM Classification:*** DSM IV***Study period:*** NR***Number of centers:*** Multicenter(n = 76)***Setting:*** Inpatient***Country:*** Spain***Financial support:*** Industry (Bristol–Myers Squibb, Otsuka)***Washout period performed:*** yes (1–3 days)***Run-in phase performed:*** no***Followup period:*** 12 wks | ***Main inclusion criteria:*** DSM–IV Dx of bipolar I disorder***Main exclusion criteria:*** Presence of rapid–cycling bipolar I disorder; duration of the current manic episode of more than 4 weeks; proven substance misuse; pts considered unresponsive to antipsychotics; recent Tx with a long–acting antipsychotic, lithium or divalproate | ***G1:******Age (mean±SD):*** 41.00 ± 11.80***Males (n(%)):*** 57/172 (31.9%)***Ethnicity:*** NR***BL symptom scores:*** BPRS (mean±SD): 4.90 ± 1.31YMRS (mean±SD): 31.50 ± 7.87***G2:******Age (mean±SD):*** 40.80±10.80 ***Males (n(%)):*** 244/336 (72.6%)***Ethnicity:*** NR***BL symptom scores:*** BPRS (mean±SD): 5.00 ± 1.32YMRS (mean±SD): 31.10 ±6.61 | ***G1:******Classification:*** FGA***Drug:*** Haloperidol***Dosage:*** 10–15mg***Intervals:*** NR***G2:******Classification:*** SGA***Drug:*** Aripiprazole***Dosage:*** 15–30mg***Intervals:*** NR |

AP = antipsychotic; BID = Twice daily; BL = baseline; BPRS = Brief Psychiatric Rating Scale; d = day; DSM = Diagnostic and Statistical Manual of Mental Disorders; FGA = first-generation antipsychotic; mg = milligram; n = number; NR = not reported; RCT = randomized controlled trial; SD = standard deviation; SGA = second-generation antipsychotic; Sz = schizophrenia; wk = week; YMRS = Young Mania Rating Scale; yr = year